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Resumé 
Colorektal cancer (CRC) er den tredje mest almindelige kræftform i Danmark, og i mellem 2007 og 
2011 døde i gennemsnit 1375 CRC patienter hvert år. Det høje dødstal kan skyldes at CRC ofte 
bliver opdaget i et sent stadie. Screeningsmetoder er i dag primært baseret på Carcinoembryonisk 
antigen (CEA) og hæmocultprøve (FOBT), men ingen af disse har vist sig særligt effektive, da de 
har en lav sensitivitet og specificitet. En god diagnostisk biomarkør bør have både en høj sensitivitet 
og specificitet, og derfor er der et behov for nye screeningsmetoder som giver mulighed for at 
opdage CRC i tidligere stadier. Undersøgelser har vist, at cirkulerende microRNA (miRNA) 
potentielt kan anvendes som diagnostiske biomarkører for CRC og dermed erstatte nuværende 
screeningsmetoder herunder CEA og FOBT. Dette projekt vurderer cirkulerende miRNA som 
diagnostiske biomarkører for CRC. Problemet undersøges gennem videnskabelige artikler, 
rapporter og faglitteratur. 
Resultater viser, at mange miRNA er fundet dysreguleret i CRC. Endvidere blev det gennem 
projektets oversigtsartikel konstateret, at den bedste diagnostiske biomarkør er et panel bestående af 
flere miRNAer. Panelet, der viste de bedste resultater, bestod af miR- 29a, - 92a og -760, som gav 
en sensitivitet på 83,30 %, en specificitet på 93,10 % og en AUC-værdi på 0,943. Resultatet tyder 
på, at miRNA paneler er lovende diagnostiske biomarkører for CRC. Der er imidlertid et behov for 
mere omfattende valideringsforsøg før miRNA kan implementeres som biomarkører for CRC. 
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Abstract 
Colorectal cancer (CRC) is the third most common cancer type in Denmark, and between 2007 and 
2011 did an average of 1375 CRC patients die each year. The high death rate could be due to that 
CRC frequently is detected in a late stage. Screening methods today are primarily based upon 
Carcinoembryonic Antigene (CEA) and Fecal Occult Blood Test (FOBT), but none of these 
screening methods have shown to be very effective, since they have low sensitivity and specificity. 
A good diagnostic biomarker should have both a high sensitivity and specificity; hence there is a 
need for new screening methods to detect CRC in early stages. Studies have shown that circulating 
microRNAs (miRNAs) can be used as potential diagnostic biomarkers of CRC, thereby replacing 
current screening methods including CEA and FOBT. This project evaluates circulating miRNAs as 
diagnostic biomarkers of CRC. The issue is examined through scientific articles, reports and 
literature. 
Results show that many miRNAs are found dysregulated in CRC. Furthermore it was found in the 
review article of the project, that the best diagnostic biomarker is a panel of multiple miRNAs. The 
panel that showed the best results consisted of miR-29a, -92a, and -760, and yielded a sensitivity of 
83.30 %, a specificity of 93.10 % and an AUC value of 0.943. The result indicates that miRNA 
panels are promising diagnostic biomarkers, but more extensive validation studies are needed 
before miRNAs can be implemented as biomarkers for CRC.  
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Introduction  
In 2012 colorectal cancer (CRC) was the third most common cancer in Denmark
1
. Between 2007 
and 2011, 2763 CRC patients were diagnosed each year, and 1375 died from CRC each year
2
. In 
order to increase the chance of survival, it is important to detect CRC in an early stage
3
. Therefore a 
national screening program is implemented in Denmark in attempt to minimize the number of 
deaths from CRC in the future
4
. Fecal Occult Blood Test (FOBT) is used in this screening 
program
4
, and if any blood is detected in the feces, a colonoscopy is conducted
5
. FOBT has a 
sensitivity of 50-59.7 %
6,7
, which means many CRC cases are missed
8
. Another biomarker available 
is Carcinoembryonic Antigen (CEA)
9
. However CEA has a sensitivity of 29.4 %
9
 and a specificity 
ranging from 30 % to 80 %
9,10
, giving many false positive and false negative cases of CRC
8
. A false 
positive subject will subsequently go through colonoscopy
8,11
, which is an invasive, expensive and 
in some cases painful method
12
, while false negative will not be examined. As current biomarkers 
have low sensitivity and specificity
4,9
, new and better screening methods are needed
12–14
.  
MicroRNAs (miRNAs) are single stranded noncoding RNAs of 22 nucleotides
15
 capable of 
regulating gene expression. It has been shown that miRNAs participate in cell proliferation, 
apoptosis, development, and differentiation
16
. Recent studies indicate that specific miRNAs are also 
important in initiation and progression of cancer, as these act as either tumour suppressors or 
oncogenes
17
. Certain miRNAs can be either down-
9
 or upregulated in patients with CRC
18
.  
Furthermore miRNA has shown to be stable in plasma, as they avoid degradation by RNases
19
. 
Mitchell et al. (2008) was the first to describe tumour-derived miRNA in plasma
19
. A number of 
studies have shown miRNAs in plasma as possible diagnostic biomarkers thereby substituting for 
CEA and FOBT. However, there is currently no agreement as to which miRNAs are the best novel 
biomarkers
9,13,14
. 
In this project we investigate the possibility of using miRNAs as a diagnostic biomarker of CRC. 
The product of this project is a review article, which serves as the result of the project. The article is 
also attached in the appendix, as an independent product. 
Aim of thesis  
Can circulating microRNAs be used as a diagnostic biomarker of colorectal cancer? 
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Intended readers 
Intended readers of this project are people who are studying biomedicine at university level. The 
review article in this project addresses scientists with knowledge in this field. 
Background 
In order to systematically review the literature of circulating miRNAs as a diagnostic biomarker of 
CRC, a review of anatomy and histology of the colon, and an overview of cancer development in the 
colon is necessary. Furthermore an insight into diagnostic methods currently used, will be 
examined to clarify why novel diagnostic biomarkers are at interest. An overview of the well-
established pathways of CRC and the general synthesis of miRNA and regulation of miRNA in CRC 
tissue will also be provided.    
Anatomy and histology of colon 
The large intestine consists of cecum, ascending colon, transverse colon, descending colon, and 
sigmoid colon as shown in figure 1
20
.The overall function of the colon is to convert chyme from the 
small intestine into feces. The chyme enters cecum from ilium.  
 
Figure 1: The figure shows the anatomy of the colon. Cecum is the first part of the large intestine. Cecum is connected to ascending 
colon, which ends in the right hepatic flexure. Transverse colon extends from right hepatic flexure and ends in left splenic flexure. 
Descending colon extends from the left splenic flexure to sigmoid colon. Sigmoid colon forms an S-shaped tube and leads to the 
rectum20,21 (Modified). 
The colon consists of a complete circular muscle layer and an incomplete longitudinal muscle layer. 
The longitudinal muscle layer forms three bands along the colon. These bands are called teniae coli. 
When teniae coli contracts it creates haustra, which is pouches along the colon. It is the pouches 
that create the wrinkled appearance
20
. 
Side 6 af 46 
 
The colon is split into four layers, which are mucosa, submucosa, muscularis and serosa
22
, see 
figure 2.  
Mucosa consists of three layers: epithelium, lamina propria, and a thin layer of smooth muscles 
called muscularis mucosae. Epithelia cells function 2-3 days and are then replaced by new cells. 
Lamina propria is a thin layer of loose connective tissue, and is the layer upon the epithelium. 
Lamina propria contains small blood vessels, nerves, lymphatic vessels and tissue. Above lamina 
propria is a thin layer of smooth muscle
22
. 
After mucosa is submucosa which is a thick connective tissue layer, containing blood, lymphatic 
vessels, and a network of neurons
22
. 
Upon submucosa is muscularis, which mainly consist of smooth muscle cells. The muscles mainly 
mix and transport chyme through the intestine. Muscularis is divided in two layers, an inner circular 
muscle layer and an outer longitunal muscle layer. Between the two layers of muscles there is a 
network of neurons. The neurons are connected to the submucosa through synapses
22
.  
The outer layer of the large intestine is serosa. Serosa is a thin layer of connective tissue, and a 
single layer of cubic epithelia cells
22
. 
 
Figure 2: The figure shows the histology of the digestive tract. The four tunics in the digestive tract are mucosa, submucosa, 
muscularis and serosa. Mucosa consists of epithelium, lamina propria and muscularis mucosae. Muscularis consists of a circular and 
a longitudinal muscle layer. Serosa consist of a connective tissue layer and a layer of epithelium20 (Modified). 
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Changes in the epithelium of mucosa can possible lead to formation of polyps that further, through 
mutations, can develop into CRC
23,24
. 
Colorectal cancer 
CRC is a heterogenous disease, meaning that CRC has different molecular pathways leading to 
different phenotypes
25
. Different gene mutations have been linked with CRC, but the precise role of 
many of these genes in the initiation and progression of cancer is yet to be understood
26
. CRC can 
be divided into sporadic CRC and hereditary CRC
25
. 
Carcinogenesis is a process in which cancer develops. It is caused by genetic mutations in cells
26
. 
Certain mutations cause the cells to lose control of normal cell proliferation, apoptosis, and 
differentiation
27
. Carcinogenesis develops through a number of mutations that makes the cell 
resistant to apoptosis. The resistance to apoptosis, is one of the reason why cancer cells can 
proliferate infinitely and accumulate as tumours
27
. CRC develops through a series of events that 
will lead to the transformation of normal mucosa cells to adenoma and then further on to carcinoma 
cells
26
.  
More than 90 % of all colorectal carcinomas are adenocarcinomas, originating from epithelial cell 
of the colorectal mucosa, which is shown in figure 3. There are other rare types of colorectal 
carcinomas. These include neuroendocrine, squamous cell, adenosquamous, spindle cell and 
undifferentiated carcinomas
28
.  
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Figure 3: The figure shows the progression of a malignant epithelial tumour. (a) Carcinoma in situ: It is originating from glandular 
epithelium of the colorectal mucosa. The cancer has not yet grown beyond the inner lining of the colon or rectum. (b) Stage I: It 
invades the wall and infiltrates the lamina muscularis mucosae and then the submucosa. (c) Stage II: It grows into and penetrates the 
muscularis propria. The cancer may begin to extend into nearby tissue. (d) Stage III: It penetrates the serosa and can then spread to 
the peritoneum and to the lymphnodes. (e) Stage IV: The tumour gains the potential to spread to other organs through metastasis. The 
tumour cells will have irregular tubular structures, with stratification, multiple lumens and reduces stroma24. 
Symptoms of colorectal cancer 
Depending on the location of the tumour the symptoms can vary. If the tumour is right sided the 
symptoms are often anemia, weight loss, pain in the abdomen and maybe a palpable mass. If the 
tumour is left sided the symptoms are often fresh blood in feces, change in defecation pattern, colic 
like pains and for some colonileus
23
. The symptoms often shows in the later stages of CRC and 
therefore screening programs are implemented for early detection of CRC
23
.   
Diagnosis of colorectal cancer 
If a person shows any symptoms connected with CRC a number of examinations should be 
performed. Patients family’s history of CRC are taken into account in the examination23.    
During the examination an abdominal palpation and a rectal-exploration are performed
23
.  
Throughout a rectal exploration, the rectum is palpated for abnormalities and enlargements
29
. 
Consecutive bleeding leading to blood in the feces can cause anemia and therefore a blood sample 
is taken to measure the hemoglobin level.  Furthermore gynecological examination is carried out for 
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women. For further examination the patient is referred to a specialist in surgery or a hospital
23
. If 
the patient only experiences fresh bleeding then a sigmoideoscopy is performed
23
.  
If there is a change in defecation without visible blood lasting for more than four weeks a 
sigmoideoscopy can be conducted. If the sigmoideoscopy shows no sign of cancer, FOBT is carried 
out. This is done to examine if any occult blood should be present in the feces. If the test is positive 
a colonoscopy is performed
23
.  
Colonoscopy is conducted if there is no fresh bleeding, or fresh bleeding together with changes in 
defecation pattern. Colonoscopy and gastroscopy is performed if the patient has anemia as a result 
of occult bleeding
23
. A computed tomography colonography can be carried out if a colonoscopy 
could not be performed
23
. 
Stages in colorectal cancer 
When CRC is diagnosed, staging of cancer is an essential step in the process of determining both 
treatment and prognosis
27
.  
The Tumour-Node-Metastasis (TNM) system is the most commonly used today
23
. TNM builds the 
classification on three criterias: Primary tumour (T), spread to the lymph nodes (N) and metastasis 
(M)
23
. The TNM system of CRC is shown in table 1. 
Stage Description 
pT0 No invasive tumour 
pT1 The tumour has invaded the submucosa, but not the muscularis propria 
pT2 The tumour invades muscularis propria, but does not penetrate it 
pT3 The tumour penetrates muscularis propria. If possible it may penetrate into the serosa or 
percolic fat (next to the colon), but not into the free peritoneal cavity (next to the rectum). It 
has not invaded other organs 
pT4 The tumour has invaded other organs  
pN0 There is no nodal metastases 
pN1 1-3 pericolic or perirectal nodes involved 
pN2 4 or more pericolic or perirectal nodes involved 
pM0 No distant metastases 
pM1 Distant metastases 
Table 1 The table shows the Tumour-Node-Metastasis (TNM) system. T refers to primary tumour, N refers to spread to the lymph 
nodes, M refers to metastasis, and p refers to, that the stages is being determined through patoanatomic examination23 
Previously, researchers used Dukes, but it is now considered out-dated because of imprecision with 
regard to prognosis
23
. A comparison between TNM and Dukes is shown in table 2.   
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Tumour status TNM Dukes 
I T1, T2 – N0-M0 A 
II A T3 – N0 – M0 B 
II B T4 – N0 – M0 B 
III A T1, T2 – N1 – M0 C * 
III B T3, T4 – N1 – M0 C * 
III C All kinds of T – N2 – M0 C * 
IV All kinds of T – All kinds of N – M1 C * or D 
Table 2 Comparison of Tumour-Node-Metastasis system TNM and Dukes. * Dukes C can be divided into C1 and C2. C2 have 
metastasis on apical lymph nodes 23 
In general, the higher the stage, the less favourable prognosis. Especially the status of the lymph 
nodes is important, because spread to the lymph nodes is the first step in the cancer spreading to 
distant organs
27
. 
Colorectal cancer pathways  
While the role of different gene mutations in the initiation and progression of cancer is yet to be 
understood, there are two well established pathways that may lead to sporadic CRC: The 
chromosomal instability pathway and the microsatellite instability (MSI) pathway
26
. Both the 
chromosomal instability pathway and the MSI pathway endow the cells with a greater degree of 
DNA instability, which eventually leads to malignant transformation. These two pathways are not 
exclusive, with some tumours exhibiting features from more than one of the two pathways
26
.  
The chromosomal instability pathway 
The chromosomal instability pathway, counts for about 65-70 % of the sporadic CRC cases. It is 
characterized by gain or loss of whole chromosomes or chromosomal regions
31
. These regions 
contain genes integral for the process of colorectal carcinogenesis. The chromosomal instability 
pathway results from defects in chromosome segregation with subsequent aneuploidy, telomere 
dysfunction or defects in the DNA damage response mechanisms
31
. Coupled with these different 
karyotype abnormalities is the accumulation of mutations in oncogenes and tumour suppressor 
genes
26
. The most common genetic alterations are mutations in the Adenomatous Polyposis Coli 
gene (APC), K-ras and/or p53 genes
26
. However it has been shown that the combination of these 
mutations in the same cancer is uncommon
32
. 
APC is a tumour suppressor gene located on the long arm of chromosome 5
26
.  Normally tumour 
suppressor genes are able to regulate cell cycle and block uncontrolled cell proliferation. Damage or 
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loss of expression of tumour suppressor genes will therefore cause the cell to lose cell cycle 
control
33
. Somatic APC mutations are seen in 60-80 % of CRC
26
. It is also seen in a large 
percentage of colorectal adenomas, which indicates that APC mutation is an early event in the 
process of colorectal tumourigenesis
34
. Colorectal adenomas are chromosomal instable and it has 
the propensity to lose, rearrange or duplicate entire chromosome segments, which results in further 
genetic mutations
26
. 
APC is a part of the Wnt/wingless pathway. This pathway plays a central role in supporting 
intestinal epithelial renewal. The Wnt pathway in the “ON” and “OFF” state is shown in figure 4. 
The APC protein binds to β-catenin and induces its degradation. It is therefore a negative regulator 
of β-catenin. A loss of APC function through in example a mutation will result in accumulation of 
cytoplasmic β-catenin and therefore translocation to the nucleus, where it will bind to T-cell factor 
(TCF), and activate the Wnt target genes
35
. The Wnt target genes affect many cellular functions, for 
example regulations of cell cycle progression, cell proliferation, angiogenesis and apoptosis. It 
therefore appears that the Wnt signalling pathway plays a central role in initiation and progression 
of CRC
35
.  
 
Figure 4: The figure shows the Wnt signalling pathway in the ”OFF” and ”ON” states. In the “ON” state the Wnt ligand binds to the 
Frizzled (Frz) receptors and activate Dishevelled (Dsh). This blocks the function of a destruction complex that is based on the 
scaffold proteins Axin/conductin. Therefore the phosphorylation and degradation of β-catenin is blocked, which will allow a nuclear 
transfer of β-catenin. In the nucleus the TCF/β-catenin complex will bind to DNA and activate Wnt target genes. The “ON” state can 
also occur due to mutations of APC. In the “OFF” state Wnt is absent, and therefore the axin/conductin complex will promote the 
phosphorylation of β-catenin by GSK3beta31. 
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Another form of genetic alterations that may occur is dysfunction of a gene called K-ras. K-ras is a 
proto-oncogene
26
. A proto-oncogene is a gene that can become an oncogene
36
. Oncogenes turn on 
or promote the process of carcinogenesis. They are involved in signal transduction, so that 
continued promotion of tumour growth can occur
27
.  K-ras is mutated in 40-50 % of CRC and large 
adenoma cases
37
. The gene product of K-ras is a membrane bound protein
26
. This protein is 
involved in signal transduction, and is activated in response to extracellular signals. The mutated 
protein is locked in the active form because of impaired GTPase activity, which hydrolyse GTP to 
GDP
26
. K-ras activation affects many cellular pathways. These pathways control cellular growth, 
differentiation, apoptosis, cytoskeleton organization, proliferation and inflammation
31
.  
The next steps in developing CRC are a continuous accumulation of mutations in the cells, which 
will give the tumour the potential of becoming a malignant tumour. Especially mutations in the 
tumour suppressor gene called p53 plays a central role in the transformation from benign to 
malignant tumour
26
. The product of p53 is a transcription factor with tumour suppressor activity, 
that binds to specific DNA sequences and activates multiple genes involved in cell cycle arrest, 
apoptosis, senescence, autophagy, and cellular metabolism
26
. 
Microsatellite instability pathway 
The MSI pathway is responsible for about 15 % of the sporadic CRC cases
25
. Microsatellites are 
short repeat nucleotide sequences that are spread out over the whole genome
33
. These are prone to 
errors during replication because of their repetitive manner
26
. The degree of instability of 
microsatellites in CRC is divided into subgroups according to the percentage of unstable MSI 
biomarkers: MSI low, MSI high and microsatellite stable
38
. In the replication there may occur 
different kinds of errors. That could for example be a base-pair mismatch. Normally the DNA 
mismatch repair system recognizes and repairs base-pair mismatches
39
. Instability of microsatellites 
is a reflection of the inability of the DNA mismatch repair system to correct these errors and is 
recognized by frame shift mutations in the microsatellite repeats
26
. CRC with MSI tend to have a 
better prognosis, but the reasons for this is still not clear
26
. 
Inheritable syndromes leading to colorectal cancer 
Approximately 5 % of all CRC cases are due to inherited genetic mutations
26
. Besides the two well-
established CRC pathways, there are two well-defined inheritable syndromes leading to CRC: 
Hereditary Non Polyposis Colorectal cancer (HNPCC) and Familial Adenomatous Polyposis (FAP). 
FAP was the first recognized and characterized colonic polyposis syndrome
26
. It accounts for less 
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than 1 % of all CRC cases
40
. FAP is inherited in an autosomal dominant disorder that is caused by 
germline mutations of the APC gene
40
. The patients with FAP will develop hundreds to thousands 
of colorectal adenomatous polyps, and will therefore have an almost 100 % risk of developing 
CRC
40
. However this risk is reduced when patient enter a screening-treatment program, which 
includes colonoscopy every second year after the person have turned 25 year
23
. 
HNPCC is another hereditary CRC syndrome, which results from germline mutations in genes 
involved in CRC carcinogenesis
26
. HNPCC accounts for 2-5 % of all CRC cases
23
. This type of 
cancer is also an autosomal dominant disorder, which is caused by germline mutations in DNA 
mismatch repair genes
26
. Loss of activity in these genes leads to replication errors with an increased 
rate of mutations and a higher potential for development of malignant tumours
26
. HNPCC is the 
most common hereditary CRC syndrome
23
. Patients with HNPCC tend to develop cancer at a 
younger age
23
. Furthermore they tend to develop proximal colon cancer and are at higher risk for 
synchronous cancers. Synchronous cancers is the development of two or more histologically 
distinct simultaneously detected malignancies
26
. Figure 5 shows progression from normal 
epithelium to CRC in both sporadic CRC and hereditary CRC. 
 
Figure 5: The figure shows the progression from normal epithelium to colorectal cancer (CRC). This requires an accumulation of 
mutations in particular genes that affect the balance between cell proliferation and apoptosis. (A) This shows the steps in 
development of sporadic CRC in normal colon epithelium. Not all colorectal tumours will gain all the mutations shown. (B) This 
shows the development of CRC in individuals with an existing cancer predisposition.  
i) Familial Adenomatous Polyposis (FAP) starts with a germline inactivation of one Adenomatous polyposis coli (APC) allele. It 
shows that the adenoma will develop faster, but that the progression from adenoma to carcinoma has the same rate as sporadic CRC.  
ii) Hereditary Non Polyposis Colorectal Cancer (HNPCC): starts with a germline inactivation of one allele of one of the mismatch 
repair genes. This will speed up the progression from adenoma to carcinoma41. 
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MicroRNA 
miRNAs are in more recent cancer literature considered as possible tumour suppressors and 
oncogenes contributing to cancer development
17
. miRNA is a type of noncoding RNA that is 
approximately 22 nucleotides long
39
. The sequence of the miRNA is complementary to particular 
parts of messenger-RNAs (mRNAs). This make miRNAs capable of regulating gene expression
42
. 
miRNAs are produced from larger RNA precursors. The RNA precursors fold back upon 
themselves creating a hairpin structure as seen in figure 6.  
 
Figure 6: The figure shows how microRNA (miRNA) is produced. miRNA genes are transcribed by RNA polymerase II (Pol II) into 
long primary miRNA (pri-miRNA) sequences. These sequences will fold into stem-loop structures. Next pri-miRNA is cleaved by 
DiGeorge syndrome critical region gene-8 complex (Drosha-DGCR8) to form pre-miRNA structures. These structures contain 2 
nucleotid overhangs at their 3’ ends. Then pre-miRNA is transported to the cytoplasm by exportin-5-RanGTP. When it is in the 
cytoplasm, pre-miRNAs are processed by Dicer into small miRNAs, that assemble into the RNA-induced silencing complex (RISC). 
RISC contains AGO2, AGO1 and other proteins. Severable RISC complexes that are loaded with miRNA (called miRISC) will bind 
to target mRNA and block the translation42 (Modified). 
Each hairpin structure, called a pri-miRNA, gives rise to one miRNA. In the nucleus the pri-miRNA 
is cut from the RNA precursor by a complex consisting of the enzyme Drosha and a protein called 
DGCR8. This creates a precursor miRNA (pre-miRNA) around 70 nucleotides long
42
. The pre-
miRNA is transported out of the nucleus to the cytoplasm by a complex consisting of the protein 
exportin-5 and Ran GTPase, which recognize a two nucleotide overhang on the miRNA created by 
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Drosha. Ran GTPase hydrolyzes GTP in the cytoplasm, and the exportin-5 and the pre-miRNA are 
released. An enzyme called Dicer cuts of the loop of the double-stranded pre-miRNA and the single 
stranded ends, to create a double stranded RNA of about 22 nucleotides, see figure 6
42
. One of the 
strands is degraded by RNA helicase, and the other strand becomes the mature miRNA
39
. Several 
proteins form a complex, named microRNA-induced silencing complex (miRISC), with the mature 
miRNA. The mature miRNA are able to bind to a mRNA that is partly complimentary or fully 
complimentary to the miRNA
42
. miRNA can regulate genes by changing the function of the mRNA 
in two ways, see figure 7.  
 
Figure 7: The figure shows how the microRNA (miRNA) binds to the messenger-RNA (mRNA). The first way is to cleave the 
mRNA, the other is to suppress the translation of it. If only parts of the miRNA sequence are complimentary to the sequence of the 
mRNA, it will suppress the translation of the mRNA by binding to the 3’ untranslated region42. If the sequence of the mature miRNA 
is nearly completely complimentary to the mRNA, the miRNA and mRNA will be cleaved39(Modified). 
 
MicroRNA in colorectal cancer 
Mitchell et al. (2008) was the first to describe tumour-derived miRNA in plasma
19
. However the 
interrelationship between miRNA levels in plasma and tissue are still not established
43,44
.Studies 
have shown that exosomes carry different functional proteins here among miRNA
45
. Exosomes are 
membrane vesicles that are released from normal cells in the body here among red blood cells. It 
has also been shown that the exosomes can be tumour derived
45
. These exosomes are transported 
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over into the circulatory system
46
. This could serve as a proposition of how tumour derived 
miRNAs are transported to the blood. Another proposition is that  tumour-associated miRNAs 
detected in circulation results from tumour cell death and lyses
47
.  
There is a big difference in the expression of miRNA in CRC tissue compared to normal colon 
tissue. Certain miRNAs are upregulated in CRC tissue, while other miRNAs are downregulated
17
.  
Regulation of microRNAs 
It has been found that certain miRNAs are upregulated in CRC
12–14,18,48–50
. Some miRNAs are found 
to function by modulating oncogenic or tumour suppressor genes. The miRNAs thereby play an 
important role in the development and progression of cancers, and may therefore function as either 
oncogenes or tumour suppressors. 
It has been suggested that miRNAs which are upregulated, have oncogenic functions that promote 
the development of CRC
51
. The miRNAs found to be upregulated in CRC is for example miR-21, 
miR-155 and miR-92a. These act as oncogenic miRNAs in CRC
52–54
. miR-21 is present in both 
adenomas and carcinomas, however a high level of miR-21 often indicates a more advanced stage 
of cancer. Therefore miR-21 is thought to regulate the initiation of malignancies
55
.  
Opposite, tumour suppressor miRNAs are downregulated in CRC
51
. miRNAs found to be 
downregulated in CRC are in example miR-143, miR-145 and miR-148b. These act as tumour 
suppressors in CRC
15,56
. miR-143 has shown in vitro to suppress proliferation and cell growth
17
. It 
suppresses by binding to the mRNA that encodes K-ras, DNMT3A and signal-regulated kinase-5, 
and thereby it blocks the translation. Categorizing miR-143 as a tumour suppressor gene, has 
mostly been because of its downregulation in tumours
17
. The underlying mechanisms of 
downregulation of miRNA in plasma remain predominantly unknown
57
, but multiple mechanisms 
have been suggested. 
First it has been suggested that miRNA is downregulated in cancer due to transcriptional 
downregulation
57
. This could for example be a regulation of miR-34. miR-34 is a tumour 
suppressor that is thought to decrease due to regulation by p53
58
.  
Secondly, recent studies suggest that epigenetic alterations play a critical role in downregulation of 
miRNA in human cancer. To test this hypothesis a group treated human breast cancer cell lines with 
histone deacetylase inhibitors in vitro, and observed alterations of miRNA levels
59
.  
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Thirdly, certain mutations might also contribute to downregulation of mature miRNA. These have 
for example been shown in patients with chronic lymphotic leukemia. It was shown that in 75 
patients, five out of 42 miRNA genes had mutated. These mutations were associated with lower 
expression of mature miR-16-1 and miR-15a
60
.  
Fourth, studies have found that DNA copy number abnormalities are involved in miRNA 
downregulation. It was found that genomic copy number loss may account for the downregulation 
of approximately 15 % of miRNAs in advanced ovarian tumours
61
.  
Lastly, some of the key proteins in miRNA biogenesis could be dysfunctional or downregulated in 
cancer. Some of these key proteins in miRNA biogenesis pathway may be dysfunctional or 
downregulated in cancer. This may further enhance tumourigenesis
57
.   
In summary transcriptional downregulation, epigenetic alterations, mutations, DNA copy number 
abnormalities or defective miRNA biogenesis pathway may each or together contribute to miRNA 
downregulation in tissue
57
. 
Because of the difference in expression of miRNAs in CRC tissue compared to normal tissue, it has 
been proposed that miRNAs can be used as minimal invasive diagnostic biomarkers for CRC
12
. 
This can be tested statistically through Receiver Operating Characteristic (ROC) curves. 
Receiver Operating Characteristic curves 
ROC-curves are graphical plots used in medical statistical analysis, to determine cut-off values for 
clinical tests, for example a test to distinguish between healthy and ill individuals, see figure 8
11
. 
The purpose of the ROC curve is to find a cut-off value that will minimize the number of false 
positives and false negatives see figure 8
62
. This is the same as maximizing the sensitivity and 
specificity
11
. If the specificity increases, then more false negative cases are identified. This means 
that the sensitivity decreases, and more ill people are diagnosed as healthy. If the sensitivity 
increases then more false positive cases are identified, which means that the specificity decreases 
and more healthy people are examined
8
. Tests can be compared, by comparing the Area Under the 
Curve (AUC) for each test
62
. The data can be both continuous, which means any value within a 
range, and discrete which are only certain values
63
. 
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Figure 8: The figure shows two different test results and their ROC curves. (A) shows a very good test with both high sensitivity and 
specificity. (B) shows what happens if either the sensitivity or the specificity increases. (C) shows the ROC-curve for the graph in A 
where there is little overlap yielding a high AUC value. (D) shows the ROC-curve for graph B where there is some overlap yielding a 
smaller AUC value8 (Modified). 
A ROC curve is created by plotting the fraction of true positives (TP) out of the total actual 
positives, which gives the true positive rate (TPR) also known as sensitivity.  Sensitivity is plotted 
versus the fraction of false positives (FP) out of the total actual negatives, which gives the false 
positive rate (FPR) at various threshold settings
64
. 
The ROC curve is then the sensitivity as a function of 1–specificity (FPR), see figure 863. 
Maximizing the sensitivity will give a large value on the vertical axis, whereas maximizing the 
specificity will give a small value on the horizontal axis se figure 8
11
.  
An example could be to hypothesize that a certain circulating miRNA as a biomarker above a 
certain value could be used to diagnose CRC. True positives are the number of patients grouped as 
CRC patients, and in reality having CRC. False positives are the number of individuals grouped as 
CRC patients, but in reality being healthy individuals. An experiment with CRC could be defined as 
P (positive) instances of CRC and N (negative) instances of CRC. The four possible outcomes for 
individuals in this experiment are listed in table 3.  
 
 
Side 19 af 46 
 
True positive (TP) Correctly diagnosed as CRC patient 
True negative (TN) Correctly identified as a healthy individual 
False positive (FP) Healthy individual diagnosed as CRC patient  
False negative (FN)  CRC patient identified as healthy individual  
Table 3: The four possible groups the individuals in the experiment can be placed in are seen in the table. 
The AUC value gives the diagnostic accuracy of the given test, see figure 9. If the AUC value is 
equal to 1, the test is 100 % accurate, because both the sensitivity and specificity is 1
11
. A 100 % 
accurate test has no type I and type II errors
65
. Type I error is to eliminate the null hypothesis, when 
it is valid, and this would represent a false positive case. A type II error is to eliminate the 
alternative hypothesis, when it is valid, and this represents a false negative case, which is defined in 
table 3
65
. When investigating certain circulating miRNA as a biomarker for CRC, the null 
hypothesis would be that miRNAs could not distinguish between CRC patients and healthy 
individuals. In other words, the value of the investigated miRNA would be the same as the control 
miRNA. The alternative hypothesis would be that the miRNA distinguish between CRC patients 
and healthy individuals; meaning that the value of the investigated miRNA is different from the 
control miRNA
65
: 
Null Hypothesis:  miRNA = Control miRNA 
Alternative Hypothesis:  miRNA ≠ Control miRNA 
AUC values are typically between 0.5 and 1
11
. The AUC value for the diagonal line in figure 9 is 
0.5
62
. For the AUC value to be 1, the ROC curve must consist of two straight lines; one vertical 
from (0,0) to (0,1) and one horizontal from (0,1) to (1,1) see figure 9
11
.  
 
 
 
 
 
 
Figure 9:  The graph shows four different lines. The diagonal line B is a ROC curve with an area under the curve (AUC) value of 
0.5. The test accuracy increase when the lines are further towards the upper left corner. The test accuracy decrease when lines moves 
towards lower the right corner11 (Modified). 
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AUC values are often given in 95 % confidence interval (CI)
11
. If one were to perform an 
experiment testing whether a certain circulating miRNA above a certain value could be used to 
diagnose CRC, the AUC value of this test would not be a true value in reality, but a value that 
could be biased by statistical errors. A CI is a range in which the true value of AUC is within. If CI 
is 95 % then it is 95 % certain that the true AUC value lies within this range set. Hence there is a 
5% chance that the AUC value lies outside this range
11
. When comparing different ROC curves, 
AUC values of each curve can be classified as seen in table 4. 
AUC value Classification 
0.90-1 Excellent 
0.80-0.90 Good 
0.70-0.80 Fair 
0.60-0.70 Poor 
0.50-0.60 Fail 
Table 4 The table shows how Area Under the Curve (AUC) values are classified when comparing Receiver Operating Characteristic 
(ROC) curves66 
The highest AUC value is considered to be the most accurate, and having a high sensitivity and 
specificity
66
. 
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Abstract 
Introduction: Studies have shown that circulating microRNAs (miRNAs) can be used as potential 
diagnostic biomarkers of colorectal cancer (CRC) thereby replacing former screening methods 
such as Carcinoembryonic Antigene (CEA) and Fecal Occult Blood Test (FOBT). 
Aim: This systematic review aims to evaluate circulating miRNAs as diagnostic biomarkers of 
CRC. 
Methods: Relevant literature was searched in PubMed. To estimate the applicability of the 
circulating miRNAs, an analysis of the area under the curve (AUC) values were examined from 
the included studies. Comparison of single miRNAs and multiple miRNA profiles were 
investigated. 
Results: In general the studies showed that the AUC values increased from single miRNA to 
multiple miRNA panels, when testing their applicability as diagnostic biomarker. Of these 
miRNA panels the best AUC value was obtained with a panel consisting of miR-29a, -92a, -760. 
The panel yielded a sensitivity of 83.30 %, a specificity of 93.10 % and an AUC value of 0.943.  
Conclusion: This review shows that miRNAs are promising as diagnostic biomarkers. 
Furthermore miRNA panels were found to be more promising than single miRNAs, since they 
yield better AUC values. More extensive validation studies are needed. 
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Introduction 
Colorectal cancer (CRC) is the third most common human cancer, and is responsible for 9.7 % of 
cancer-related incidences worldwide
67
. In order to increase the chance of survival, it is important to 
use good screening methods to detect CRC in an early stage
3
. Some of the screening methods 
available today are Carcinoembryonic Antigen (CEA) and Fecal Occult Blod Test (FOBT). 
However CEA and FOBT, have low sensitivity and specificity, giving many false positive cases and 
false negative cases of CRC
4,9
. A false positive subject of CEA and FOBT will subsequently go 
through a colonoscopy, which is an invasive, expensive and in some cases painful method
12
. This 
has led to the studies of new screening methods for early detection of CRC with higher specificity 
and sensitivity
13,14
. 
MicroRNAs (miRNAs) are single stranded noncoding RNAs of 22 nucleotides
15
, capable of 
regulating gene expression. Studies have shown that miRNAs participate in cell proliferation, 
apoptosis, development, and differentiation
16
. Recent studies indicate that specific miRNAs are 
important in initiation and progression of cancer, as they act as either tumour suppressors or 
oncogenes depending on the cellular environment in which they are expressed
17
. Mitchell et al. 
(2008) was the first to describe tumour-derived miRNAs in plasma
19
. Moreover miRNAs in plasma 
have shown to be stable as they avoid degradation by RNases
19
. A number of studies have shown 
miRNAs to be possible diagnostic biomarkers, which could substitute for the CEA and FOBT. 
It is still uncertain whether miRNA can be used as biomarkers of CRC. Currently the literature 
present very different results of circulating miRNA expression in CRC patients compared to healthy 
control subjects.  
This qualitative systematic review gathers results from available studies in order to evaluate, 
whether circulating miRNAs potentially can be used as biomarkers in CRC.  
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Methods  
Data sources and search strategy 
In search of studies comparing circulating miRNA levels in plasma and serum from CRC patients 
and healthy individuals, a PubMed search was performed from 1966 up to March 2014. The search 
was performed with the following search criteria: ("coloncancer" OR "colon cancer" OR "colorectal 
cancer" OR "colorectalcancer" OR "CRC" OR "CC") AND ("microRNA" OR "miR" OR 
"miRNA") AND ("plasma" OR "circulating" OR "serum"). 
Inclusion and exclusion criteria 
Based on titles, abstracts or full texts, articles including the following criteria were included: (1) 
circulating miRNA in plasma samples from CRC patients; (2) comparison of circulating miRNA 
levels in CRC patients and healthy control subject; (3) statistical analysis of obtained data must 
include Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) values. 
Studies were excluded if they had any of the following subjects:  (1) reviews; (2) written in any 
other language than English; (3) not miRNAs; (4) not cancer; (5) other cancer types than CRC or 
CC; (6) miRNA levels based only on tissue samples, thus not circulating miRNA; (7) miRNA as 
prognostic marker for risk of metastasis, relapse or poor outcome to chemotherapy; (10) based on 
stem cells or cell cultures.  
Figure 10: The figure shows the data selection. Eight articles were included in the systematic review. 
•  21 articles excluded: 
 18 reviews, 3 not english 
89 articles identified through database searching 
•  36 articles excluded: 
 14 not cancer, 4 metastasis, 1 prognostic biomarker, 8 other cancer 
 types than CRC and CC, 3 not miRNAs, 1 therapeutic effect, 2 stem 
 cells, 2 relapse, 1 sex hormone 
68 article titles read 
•  14 articles excluded:  
 5 miRNA levels based only on tissue samples, 3 therapeutic effect, 2 
 other cancer types than CRC and CC, 1 relapse, 1 cell culture, 1 
 metastasis, 1 not available 
32 article abstracts read 
•  10 articles excluded: 
 3 prognostic biomarkers, 1 other cancer types than CRC and CC, 1 cell 
 culture, 1 miRNA levels based only on tissue samples, 4 missing AUC 
 values. 
18 full articles read 
8 articles included in the systematic review 
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Results 
Data selection 
In selection of studies comparing circulating miRNA levels in plasma from CRC patients and 
healthy individuals, 89 articles were identified as potentially relevant. After careful selection 
according to in- and exclusion criteria as described above, eight articles were included in this 
review. Study selection flow-chart is seen in figure 10.  
The studies included a total of 777 cases of CRC and 687 control subjects. Sample population 
ranged from 71 to 329. Applicability of findings from the eight studies comparing circulating 
miRNA levels in plasma in CRC patients and healthy controls were compared. Comparison was 
based on ROC curve analysis. AUC values of each curve was classified after the following ranges: 
0.90-1= excellent; 0.80-0.90 = good; 0.70-0.80 = fair; 0.60-0.70 = poor; 0.50-0.60 = fail
66
, see table 
5. 
Excellent 
We found only one study which presented a panel of miRNA with an AUC value in the range of 
0.90-1.00. The miRNA panel consisted of three miRNAs, miR-760, -291 and -92a and had an AUC 
value of 0.943
9
, see table 7. The sensitivity and specificity was 83.3 % and 93.1 % respectively. The 
result was based on 168 independent age and gender-matched individuals (100 CRC patients and 68 
healthy controls) using quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
9
. We did 
not find any studies with single miRNA profiles of AUC values above 0.90, see table 6.  
Good 
We found three different studies with four single miRNA profiles with AUC values in the range of 
0.80-0.90, see table 5. Huang et al. (2009) found miR-29a with an AUC value of 0.844 and miR-
92a with 0.838. The sensitivity was 69 % and 84 % respectively, and the specificity was 89.1 % and 
71.2 % for 29a and 92a respectively. The study was based on qRT-PCR with 120 CRC patients and 
59 healthy controls
14
. Ng et al. (2009) used microarray and qRT-PCR and found miR-92 with the 
AUC value of 0.885 in a study based on 130 CRC patients and 75 healthy controls. The sensitivity 
was 89 % and the specificity was 70 %
12
. Wang et al. (2014) found miR-93 with the AUC value of 
0.893 in a study based on 124 CRC patients and 117 healthy controls. They performed microarray 
and qRT-PCR. The data concerning sensitivity and specificity was not available
13
. Furthermore we 
found four studies with a total of five miRNA panels with AUC values in the range of 0.80-0.90. 
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Giráldez et al. (2013) found two miRNA panels. The first panel consisted of miR-19a and -19b with 
an AUC value of 0.82 together with a sensitivity of 78.57 % and specificity of 77.36 %. The second 
panel consisted of miR-19a, -19b and -15b with an AUC value of 0.84, see table 7. The sensitivity 
and specificity was 78.57 % and 79.25 % respectively. Giráldez and colleagues (2013) preformed 
microarray and qRT-PCR. The study was based on an independent cohort of 63 CRC patients and 
73 healthy controls
49
. 
Huang et al. (2009) created a miRNA panel consisting of miR-29a and -92a with an AUC value of 
0.883. The sensitivity and specificity of the panel was 83 % and 84.7 %
14
. Moreover Kanaan et al. 
(2013) had a miRNA panel consisting of two miRNAs, miR-431 and -139-3p with an AUC value of 
0.829. The sensitivity and specificity for the panel was 91 % and 57 %. The study was based on 45 
CRC patients and 26 healthy controls
48
. Kanaan et al. (2013), used microarray and qRT-PCR
48
. In 
another study by Wang and colleagues (2014) a miRNA panel consisting of miR-7, -93 and -409-3p 
with an AUC value of 0.866, was presented. The sensitivity was 91 % and the specificity was 
88%
13
. 
Fair 
In the range of 0.70-0.80 we found five studies with a total of 11 different single miRNA AUC 
values, see table 5. 
Giráldez et al. (2013), found six different single miRNA with AUC values in the range of 0.70-0.80 
(miR-18a, -19a, -19b, -15b, -29a, -335). The data concerning sensitivity and specificity was not 
available
49
. Furthermore Ng et al. (2009) found one single miRNA (miR-17-3p) with an AUC value 
of 0.717 with a sensitivity of 64 % and a specificity of 70 %
12
. Wang et al. (2012) found two single 
miRNAs (miR-601, -760) with AUC values of 0.747 and 0.788 respectively. For miR-601 the 
sensitivity was 69.2 % and the specificity was 72.4 %. For miR-760 the sensitivity was 80 % and 
the specificity was 72.4 %
9
. Furthermore Wang et al. (2014) found one single miRNA (miR-25) 
with an AUC value of 0.773. The data concerning sensitivity and specificity was not available
13
. 
Zanutto et al. (2014) found one single miRNA (miR-378) with an AUC value of 0.796. The study 
was based on a cohort consisting of 65 CRC patients and 70 healthy controls. The data concerning 
sensitivity and specificity was not available
50
. Luo et al. (2013) created a miRNA panel with 12 
miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, - 145, -181b, -342-3p and -532-3p) 
with an AUC value of 0.745. The study was based on an independent cohort consisting of 130 CRC 
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patients and 199 healthy controls. The data concerning sensitivity and specificity was not 
available
18
. 
Poor 
In the range of 0.60-0.70 we found two studies with a total of two different single miRNA AUC 
values. Wang et al. (2014) found one miRNA (miR-409-3p) with an AUC value of 0.604. The data 
concerning sensitivity and specificity was not available
13
. Zanutto et al. (2014) found one miRNA 
(miR-21) with an AUC value of 0.647. The data concerning sensitivity and specificity was not 
available
50
. 
Fail 
In the range of 0.50-0.60 we found one study with a single miRNA AUC value. Wang et al. (2014) 
presented one miRNA (miR-7) with an AUC value of 0.593. The data concerning sensitivity and 
specificity was not available
13
. 
Below fail 
A single study by Zanutto et al. (2014) found two single miRNAs (miR-135b and -204) with an 
AUC value below 0.50. miR-135b had an AUC value of 0.477, and miR-204 had an AUC value of 
0.492
50
. 
Classification of AUC values 
Applicability AUC value Number of single 
microRNA AUC values 
Number of multiple 
microRNA panel AUC 
values 
Excellent 0.90-1.00 0 1 
Good 0.80-0.90 4 5 
Fair 0.70-0.80 11 1 
Poor 0.60-0.70 2 0 
Fail 0.50-0.60 1 0 
Below fail <0.50 2 0 
Table 5: The table shows the number of miRNAs found in the eight studies sorted in the five categories Excellent, Good, Fair, Poor, 
Fail and Below fail for single miRNA profiles and multiple miRNA profiles. The ranging is based on Area Under the Curve (AUC) 
values66.  
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Single gene microRNA profile 
Author n = CRC 
/ control 
Reference 
gene 
Upregulated 
microRNA 
Downregulated 
microRNA 
AUC 
Zanutto et 
al. (2014)
50
 
65 / 70 miR-16 miR-21, -135b, -378 miR-204 0.647 ; 0.477  
0.796 ; 0.492 
Wang et al. 
(2014)
13
 
124 / 117 miR-1228 miR-409-3p miR-25, -7, -93 0.604 ; 0.773 
0.593 ; 0.828 
Giráldez et 
al. (2013)
49
 
63 / 73 miR-16 miR-18a, -19a, -19b, -
15b, -29a, -335 
 0.70-0.80 
Luo et al. 
(2013)
18
 
130 / 199 miR-16 miR-18a, -20a, -21, -
29a, -92a, -106b, -133a, 
-143, -145 
  
Wang et al. 
(2012)
9
 
100 / 68 miR-16  miR-601, -760 0.747 ; 0.788 
Huang et al. 
(2010)
14
 
120 / 59 miR-16 miR-29a, -92a  0.844 ; 0.838 
Ng et al. 
(2009)
12
 
130 / 75 RNU6B miR-17-3p, -92  0.717 ; 0.885 
Table 6: Shows number of patients, reference gene, regulation and Area Under the Curve (AUC) values of single gene microRNA 
profiles. n = number of patients in the study population. 
Multiple gene microRNA profiles 
Author n = CRC 
/ control 
Reference 
gene  
microRNA panel AUC 
Wang et al. 
(2014)
13
 
124 / 117 miR-1228 miR-93, -7, -409-3p 0.866 
Giráldez et al. 
(2013)
49
 
63 / 73 miR-16 miR-19a, -19b 0.82 
Giráldez et al. 
(2013)
49
 
63 / 73 miR-16 miR-19a, -19b , -15b 0.84 
Kanaan et al. 
(2013)
48
 
45 / 26 RNU6B miR-431, -139-3p 0.829 
Luo et al. 
(2013)
18
 
130 / 199 miR-16 miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -
143, -145, -181b, -342-3p, -532-3p 
0.745 
Wang et al. 
(2012)
9
 
100 / 68 miR-16 miR-29a, -92a, -760 0.943 
Huang et al. 
(2010)
14
 
120 / 59 miR-16 miR-29a, -92a 0.883 
Table 7 shows Area Under the Curve (AUC) values of mutilple gene microRNA profiles. n = number of patients in the study 
population. 
Discussion 
This review provides an overview of studies concerning miRNA as biomarkers for CRC diagnosis 
published before March 2014. We have summarized the results of eight studies comparing miRNA 
levels in plasma from CRC cases and healthy control subjects. These studies presented a total of 25 
dysregulated miRNAs in CRC patients either upregulated or downregulated. Among these eight 
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studies a total of 21 miRNAs were grouped in seven different miRNA panels to serve as potential 
biomarkers, while a total of 17 single miRNAs were present as potential biomarkers. 
MicroRNA panel versus single microRNA 
Currently it is uncertain whether single miRNAs or a combination of miRNAs in a panel is the most 
promising as a diagnostic biomarker of CRC
9,12–14,18,48–50
. Huang et al. (2010) examined miR-29a 
and -92a, and found AUC values of 0.844 and 0.838 respectively see table 6. When they combined 
the two miRNAs in a panel, the AUC value increased to 0.883 due to an increase in the sensitivity 
and specificity
14
. If this panel was to be implemented as a diagnostic biomarker, it would mean that 
most of the patients were correctly identify as CRC patients, and more of the controls were 
correctly identified as healthy. Even though some of the AUC values for single miRNA are quite 
good, the multiple miRNA panels AUC values were generally better. Kanaan et al. obtained a 
sensitivity of 91 % and a specificity of 57 % for their miRNA panel (miR-431, -139-3p)
48
. This 
means that many will be tested positive correctly but the low specificity means that many will be 
tested positive while they actually are healthy. Wang et al. (2012) investigated two single miRNAs 
(miR-760 and miR-601), both found to be downregulated. They created and tested a panel 
consisting of three miRNAs (miR-760, -29a, 92a) creating an AUC value of 0.943. They used miR-
760 in the panel because it had a better sensitivity as a single miRNA than miR-601. miR-29a and -
92a were added to the panel based on results from previous studies
9,14
. When comparing single 
miRNAs with multiple miRNA panels, the AUC value increased significantly from the single 
miRNA to the miRNA panel
9
. Though Huang et al. (2010) and Wang et al.(2014) obtained good 
specificity and sensitivity values Wang et al. (2012) obtained the best AUC value, see table 7, and is 
therefore the most promising miRNA panel found in this review
9,13,14
. 
Several CRC screening tests are available today. These include FOBT and CEA
14
. However 
because of low sensitivity and high cost, none of these are ideal as diagnostic screening tools
13,14,68
. 
FOBT has a sensitivity of 50-59.7 % and furthermore there is a great discrepancy between the 
investigated studies
6,7
.  CEA has shown a diagnostic sensitivity of 29.4 % and has shown a 
specificity ranging from 30-80 %
9,10
. The low sensitivity indicates that more ill people are 
diagnosed as healthy, than what actually is the case. In this review CEA would be classified in the 
category fail, see table 5, and is therefore not in our opinion a useful novel diagnostic biomarker of 
CRC. The AUC values of single miRNAs are better than the AUC-value of CEA, but they are still 
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not optimal and therefore a panel of circulating miRNA markers may improve the sensitivity and 
specificity of CRC screening.  
Microarray  
Five out of eight studies used microarray prior to qRT-PCR to examine the expression of circulating 
miRNAs
12,13,18,48,49
. Microarray gives the possibility of searching for a very large number of 
miRNAs
69
. This is used to clarify which miRNAs to work with during qRT-PCR. The studies by 
Huang et al. 2010 and Zanutto et al. 2014 did not use microarray, instead they chose miRNAs based 
on previous studies
14,50
. miRNA selection based on literature includes some of the commonly used 
miRNA, however there could be several other dysregulated miRNAs in the samples, that a 
microarray possibly could discover. Therefore it is an advantage to use microarray prior to qRT-
PCR, to assure that other dysregulated miRNAs than those found in the literature will be evaluated. 
Reference genes for normalization of quantitative real-time polymerase chain reaction 
Among the eight studies reviewed there are no consensus regarding endogenous reference gene for 
normalization of qRT-PCR, but miR-16 is the most frequently used
13,14,48
. Consensus is needed to 
evaluate the more correct applicability of miRNA as biomarkers of CRC. Normalization is an 
important step for accurate quantification of RNA levels with qRT-PCR
14
. From the eight studies 
reviewed in this article, miR-16, RNU6B, and miR-1228 were used as reference gene for qRT-PCR, 
see table 6. The discrepancy of miRNAs across different studies could possibly be caused by 
difference in the reference gene used for normalization. Huang et al (2010) found that miR-29a and 
miR-92a were significantly elevated in CRC plasma compared to healthy controls. They used miR-
16 as a reference gene
14
. In contrast Wang et al (2014) found that miR-92a showed lower 
expression in CRC compared to healthy controls using miR-1228 as a reference gene
13
.  
It is essential for the study outcome that the reference gene is stable, for them to be used as controls. 
miR-16 has shown high stability in plasma for healthy individuals and CRC patientes
49
, but there is 
a high level in red blood cells
44
. Kirschner et al. (2011) showed that if the plasma samples had 
undergone hemolysis, it yielded a significant variation in miR-16 levels
70
. There have also been 
reports of problems with the stability of RNU6B
71
. RNU6B is a small nuclear RNA
72
. Huang et al 
(2010) compared miR-16 and RNU6B, and found that miR-16 was a better reference gene, because 
RNU6B showed to be unstable at room temperature
14
. 
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In a study by Hu et al. 2014, different reference gene, including miR-16, RNU6B and miR-1228, 
were tested, to see which had the best potential as a reference gene in various types of cancers 
including CRC
73
. They excluded RNU6B for further validation because it did not pass their quality 
control. In total they found that miR-1228 was the best reference gene, because it showed much less 
variation than miR-16
73
. 
Specificity of microRNAs in diagnosis of colorectal cancer 
miRNAs are a major part of gene regulation in all cells, and certain circulating miRNAs have 
shown to be expressed by other cancer types than CRC
74
. Several studies have shown miR-21 to be 
upregulated in CRC, but it has also shown upregulation in breast cancer, gastric cancer, lung cancer, 
and esophageal cancer. Therefore it is important to examine whether the miRNAs used to diagnose 
CRC are dysregulated in other cancer types, or even in other kinds of diseases
12,74,75
. Some studies 
have already taken this into account. Ng et al. (2009) showed that elevation of miR-92 was not 
caused by either inflammatory bowel disease or gastric cancer
12
. 
In summary miRNA panels are more promising as diagnostic biomarkers than single miRNAs, 
since they have better AUC values and higher sensitivity and specificity. More extensive validation 
studies are needed along with consensus about reference gene to ensure that the results are valid. 
Furthermore future studies should take into account that the same circulating miRNAs can be 
dysregulated not only in CRC but also in other cancer types and other diseases. 
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Discussion 
In the review article it was found, that miRNA panels are promising diagnostic biomarkers. The 
discussion of this project covers the screening methods CEA and FOBT compared to miRNAs. 
Furthermore the interrelationship of miRNA in plasma and tissue, the different pathways in CRC, 
and the levels of certain miRNAs at different clinical stages will be discussed. Lastly a discussion of 
the contradictory results will be covered. 
Development of new screening methods  
An ideal screening method should have both high sensitivity and high specificity
8,11
.  If high false 
positive or negative rates are related to biomarkers, the biomarkers will be considered ineffective 
and cannot be used
11
. FOBT and CEA are not optimal screening tools
13,14,68
. FOBT has low 
sensitivity and CEA has low sensitivity and specificity
9,13,76
. 
In a study by Wang Q et al. (2012) miRNAs were compared with CEA values, to detect possible 
complementation of plasma miRNA and CEA for early detection of CRCs. The CEA data were 
compared with miR-601 and miR-760 levels in 511 stage I and II patients. They found that miR-
601 identified 26 cases of CRC that CEA had missed and also that miR-760 identified 29 missed 
CRC cases. A combined use of miR-601 and miR-760 detected 30 CEA-missed cases of CRC in 
total. Furthermore they performed ROC curve analysis that showed that combining miR-601 and 
miR-760 improves the diagnostic sensitivity of CEA from 29.4 % to 80.4 % with an AUC value of 
0.805 and a specificity of 65.5 %
9
. This also indicates that a combination of miRNAs together with 
other types of biomarkers could improve the diagnostic value. The study by Wang Q et al. (2012) 
was based on a total number of 100 CRC patients and 68 healthy individuals.  
A general concern in study design is selection of the controls. If the number of exclusion criteria for 
the control group is very large, the population will be likely to give an unrepresentative result. 
Classification rules could be to exclude various groups, for example subject with other diseases, 
smokers and obese, from the control group, which could give an unrepresentative result, in 
discriminating between cancer patients and control subjects. Control groups should be randomized 
to ensure that the results are representative and not biased
8
. The biomarker profile between the 
different stages of CRC may differ, therefore cancer patients in all stages should be included. 
It is not always possible to achieve both high specificity and sensitivity, and in such cases one have 
to choose whether a higher specificity or high sensitivity is preferable. There are advantages and 
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disadvantages associated with both decisions. If a high sensitivity is chosen at the cost of 
specificity, the rate of true positive and false positive increases while false negative decreases
8
. This 
means that more people will be correctly declared ill, but also that more people will be declared ill 
while being healthy. A consequence of this is that healthy people are unnecessary examined, which 
is expensive and may cause harm through invasive diagnostic procedures
11,23
. If a high specificity is 
chosen at the cost of sensitivity, the rate of true negative and false negative increases while false 
positive decreases
8
. This means that some people will be correctly declared ill, but also that more 
people will be declared healthy while being ill. An outcome of this is that money will be saved on a 
lot of unnecessary examinations, but at the cost of ill people being diagnosed as healthy
8
.  
In summary, if it is important to find all of those who are ill, it is necessary to have a high 
sensitivity. If it is important to exclude those who are healthy from further examination it is 
necessary to have a high specificity
8
. miRNAs has shown to have an increased sensitivity and 
specificity compared to FOBT and CEA, however more extensive validation studies are needed to 
confirm this
9,14
.  
MicroRNA in plasma and tissue 
It has been proposed that circulating miRNAs can originate from cancer cells
50
. However Pritchard 
et al. (2012) showed that many of the circulating miRNAs suggested as biomarkers of CRC, are 
also highly expressed in normal red blood cells
44
. To examine whether the miRNAs originates from 
the blood or the cancer tissue, some studies compare the levels of miRNAs in tissue from CRC 
patients and healthy individuals and circulating miRNA levels in ill and healthy individuals
9,43
. 
Toiyama et al. (2013) compared the levels of miR-21 and -31 in tissue of ill and healthy versus 
circulating miRNA levels in ill and healthy. They found that both miRNAs in the tumour tissue was 
significantly elevated, but in plasma samples they only found miR-21 to be significantly elevated
43
. 
In a study it was found that two miRNAs (miR-601 and miR-760) was decreased in CRC plasma 
but not similar decreased in CRC tissue
9
. Not all studies make the comparison between tissue and 
plasma which could be a disadvantage. Of the eight studies reviewed three makes this 
comparison
9,12,50
. Comparison of the miRNA levels in tissue versus plasma is important, to assure 
that the miRNAs examined are derived from the tumour tissue. If there is a correlation between the 
levels of miRNA in blood and the levels of miRNA in tissue, it is a good indication that it can be 
used as a diagnostic biomarker.  
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Colorectal cancer pathways and microRNA 
Few studies have investigated the correlation between the chromosomal instability pathway and 
miRNA and the microsatellite pathways and miRNA
14,18,35,47,77–84
. 
The chromosomal instability pathway and microRNA 
APC and miR-135b  
miR-135b has been found to target the 3’UTR of APC and repress the expression of APC77. 
Repression of APC will increase the Wnt pathway, since β-catenin no longer will be degraded and 
accumulate
77
. Accumulation of cytoplasmic β-catenin will activate the Wnt target genes35. miR-
135b possibly has the same effect on APC, as the loss of function of APC in the chromosomal 
instability pathway
85
. Nagel et al. (2008) showed miR-135b to be significantly upregulated in 
colorectal adenoma tissue and carcinoma tissue
77
. miR-135b could in the CRC cases investigated by 
Nagel et al. (2008) possibly contribute to early development of CRC, by regulating the APC gene
77
.   
MicroRNA and p53  
The expression of some miRNAs is regulated by p53, and are thereby considered as tumour 
suppressors
78,79
. A study by Suzuki et al. (2009) has shown that p53 in response to DNA damage, 
upregulates miR-143 and miR-145
79
. Upregulation of miR-143 and miR-145 happens by promoting 
processing of pri-miRNAs to pre-miRNAs of miR-143 and miR-145
79
. p53 mutations could 
therefore also explain why regulation of the processing of miRNA changes. This could further 
explain why miR-143 and miR-145 has been found in some studies to be downregulated in 
CRC
78,80,81
. However, Lou et al. (2013) showed that miR-143 and miR-145 were significantly 
upregulated in the plasma of CRC patients compared to controls
18
.  
On the other hand, the expression and activity of p53 is also regulated by miRNAs
78,82
. Other 
miRNAs, which target the p53 expression, may have oncogenic potential, if they can suppress 
signals mediated by p53
78
. A study has shown that miR-504 can negatively regulate p53 by binding 
to the p53 3’UTR region82. miR-125b has also shown ability to regulate p53 by binding to the p53 
3’UTR region83. Upregulation of miR-504 and miR-125b can therefore reduce p53 activity and 
contribute to tumourigenesis
82
.  
MicroRNA and K-ras 
A study by Chen et al. (2009) showed that miR-143 could suppress CRC cell growth by inhibiting 
translation of K-ras oncogene
81
. Chen et al. (2009) also showed that miR-143 was significantly 
downregulated in CRC tissue compared to normal tissue, and K-ras protein levels were 
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significantly increased
81
. This may explain why downregulation of miR-143 could promote 
tumourigenesis
81
.  
The up- or downregulation of miRNAs can be a result of chromosomal additions or deletions
86
. 
Above mentioned studies indicate that miRNAs can act likewise, or maybe be a part of, the 
chromosomal instability pathway by regulating APC, p53 or K-ras
35,77,78,81–83,85
. 
MicroRNA and microsatellite pathway 
A study examined miRNA expression and the MSI pathway, by comparing miRNA expression in 
CRC tissue with MSI low status, MSI high status and microsatellite stable status
84
. Expression of 
miR-92, -223, -155, -196a, -31, and -26b was found to be significantly different among MSI 
subgroups, and miR-31 and miR-223 were overexpressed in CRC of patients with HNPCC
84
. These 
results indicate that miRNA expression in CRC is different in MSI subgroups, including MSI low 
and HNPCC-associated cancers
84
. Therefore miRNAs seems to play a central role in the 
microsatellite pathway
84
. These results are based on miRNA levels in tissue. It is still uncertain if 
the miRNAs involved in CRC pathways is upregulated in the same way in plasma as in tissue. 
Another uncertainty is how miRNA can be downregulated in plasma. 
Downregulation of microRNA 
No study has been found, explaining why the miRNAs are downregulated in the circulatory system. 
Further investigation has to be done, in order to understand the underlying mechanisms of 
downregulation of miRNA in the circulatory system to assess whether downregulated miRNAs can 
be used as diagnostic biomarkers of CRC
9
.  
We believe that cancer can cause global downregulation of miRNAs in the human body. Cancer 
does not only affect the organ were the cancer originate but also the surrounding tissues and the 
immunosystem causing the homeostasis to be disrupted
87
. miRNAs are expressed by all cells in the 
body. It is therefore a possibility that cancer can cause global downregulation, since some miRNAs 
seem to be downregulated in plasma.  
Levels of microRNAs in different stages of colorectal cancer 
We believe that a good diagnostic biomarker should be detectable in all stages of cancer. Slaby et 
al. (2008) found that the expression of miR-21 correlates with the development of cancer. Higher 
levels of miR-21 indicate higher levels of clinical stage, lymph node status and the development of 
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distant metastasis. This shows that elevated levels of circulating miR-21 is associated with poor 
prognosis
15
. 
Another study found five miRNAs (miR-34a, -146a, -21, -484, -425) whose expression was 
different in the early and late stages of CRC
88
. miR-484 and -21 were significantly elevated in stage 
IV compared to controls, but had a lower expression in stage I-II
88
. miR-34a were significantly 
elevated in stage I-II and had a lower expression in stage IV compared to controls. Furthermore 
miR-146a showed a significant low expression in stage IV, but no significant changes in stage I-II 
patients. miR-425 was significantly lower in expression in stage I-II, but showed no significant 
changes in stage IV compared to controls
88
. The difference in miRNA expression in the different 
stages is a strong indicator, that some of the miRNAs can be used as both a diagnostic and 
prognostic biomarker.  
Contradictory results 
Even though many studies show that certain miRNAs can be used as diagnostic biomarkers there 
are studies showing opposite results
12,14,18,49,89
. Ng et al. (2009) found miR-17-3p and -92 to be 
upregulated. This is in contradiction with a study carried out by Faltejskova et al. (2012). They 
found that miR-17-3p and -92 did not differ significantly from the circulating miRNA level in 
healthy controls
89
. This could partly be due to the use of different reference genes. Ng et al. (2009) 
used RNU6B and Faltejskova et al. (2012) used miR-16
12,89
.  
Furthermore Faltejskova et al. (2012) found miR-29a to be downregulated while Huang et al 
(2010), Giráldes et al. (2013) and Luo et al. (2013) found mir-29a to be upregulated
14,18,49,89
.  
Faltejskova et al. (2012) based their study population on Caucasians whereas Huang et al. (2010) 
and Ng et al. (2009) obtained data from Chinese clinics and therefore it is reasonable to assume that 
the majority of the study population consists of Mongoloid
12,14,89
. Faltejskova et al. (2012) mentions 
that the lack of consensus between study populations could cause the different results
89
. However 
results from Huang et al. (2010) and Ng et al. (2009) were supported by Giráldes et al. (2013) and 
Luo et al. (2013) who used a Caucasian study population and found the same miRNAs (miR-92a, -
29a and -17-3p) to be upregulated
12,14,18,49
.     
Furthermore population size ranging from 130 to 329 could also contribute to the different 
outcomes
18,89
. The fact that Luo et al. (2013) uses a bigger population group, could make their study 
a better representative of the reality than a smaller study population does
18
.  
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Zanutto et al. (2014) obtained the same results as Faltejskova et al. (2012)
50,89
. They also found that 
the levels of miR-29a and miR-92a could not be associated with CRC. They suggest that the 
different results could be due to difference in ethnicity, but they also imply that it can be due to the 
fact that many circulating miRNAs do not originate from cancer cells
50,89
. Pritchard et al. (2011) 
showed that miR-92a and miR-29a are expressed by red blood cells, and that hemolysis can raise 
the expression 50-fold
44
. Zanutto et al. (2014) based their study on samples with a narrow 
hemolysis ratio, and justify that this could be the reason why no difference was found in the level of 
circulating miR-29a and miR-92a between healthy and ill patients
50
. 
In summary, the results by Faltjeskova et al. (2012) and Zanutto et al. (2014) is in contradiction 
with the studies by Ng et al. (2009), Huang et al. (2010), Giráldes et al. (2013) and Luo et al. 
(2013), and thereby suggesting that miR-17-3p, -92a and -29a are not promising biomarkers for 
detecting CRC.  
Conclusion 
Through this project it has been found that miRNA panels are promising as diagnostic biomarkers, 
and therefore are possible substitutes for CEA and FOBT. However it is important to achieve a 
better understanding of the miRNA pathways in CRC, the interrelationship between miRNA levels 
in plasma and tissue, and the mechanisms concerning the downregulation of miRNAs. Furthermore 
more extensive validation studies are needed before miRNAs can be used as biomarkers for CRC.  
Future perspectives 
Circulating miRNAs have shown to be used as possible diagnostic biomarkers in CRC and should 
be produced as a panel of different miRNAs. It has also been shown that some of the circulating 
miRNAs found to be dysregulated in CRC are also dysregulated in other cancer types
74,90
. Currently 
it is more likely that circulating miRNAs can be used as a diagnostic biomarker for cancer in 
general, rather than a specific cancer type. Based on current studies there are potential for a specific 
diagnostic biomarker
9,12–14,18,48–50
. Through further studies specific miRNAs for certain cancer types 
should be examined, this could lead to a specific diagnostic miRNA panel for particular cancer 
types in the future. 
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Abstract 
Introduction: Studies have shown that circulating microRNAs (miRNAs) can be used as potential diagnostic biomarkers of colorectal 
cancer (CRC) thereby replacing former screening methods such as Carcinoembryonic Antigene (CEA) and Fecal Occult Blood Test 
(FOBT). 
Aim: This systematic review aims to evaluate circulating miRNAs as diagnostic biomarkers of CRC. 
Methods: Relevant literature was searched in PubMed. To estimate the applicability of the circulating miRNAs, an analysis of the 
area under the curve (AUC) values were examined from the included studies. Comparison of single miRNAs and multiple miRNA 
profiles were investigated. 
Results: In general the studies showed that the AUC values increased from single miRNA to multiple miRNA panels, when testing 
their applicability as diagnostic biomarker. Of these miRNA panels the best AUC value was obtained with a panel consisting of miR-
29a, -92a, -760. The panel yielded a sensitivity of 83.30 %, a specificity of 93.10 % and an AUC value of 0.943.  
Conclusion: This review shows that miRNAs are promising as diagnostic biomarkers. Furthermore miRNA panels were found to be 
more promising than single miRNAs, since they yield better AUC values. More extensive validation studies are needed. 
Introduction 
     Colorectal cancer (CRC) is the third most common human cancer, 
and is responsible for 9.7% of cancer-related incidences worldwide1. 
In order to increase the chance of survival, it is important to use good 
screening methods to detect CRC in an early stage2. Some of the 
screening methods available today are Carcinoembryonic Antigen 
(CEA) and Fecal Occult Blod Test (FOBT). However CEA and 
FOBT, have low sensitivity and specificity, giving many false 
positive cases and false negative cases of CRC3,4. A false positive 
subject of CEA and FOBT will subsequently go through a 
colonoscopy, which is an invasive, expensive and in some cases 
painful method5. This has led to the studies of new screening 
methods for early detection of CRC with higher specificity and 
sensitivity6,7. 
     MicroRNAs (miRNAs) are single stranded noncoding RNAs of 
22 nucleotides8, capable of regulating gene expression. Studies have 
shown that miRNAs participate in cell proliferation, apoptosis, 
development, and differentiation9. Recent studies indicate that 
specific miRNAs are important in initiation and progression of 
cancer, as they act as either tumour suppressors or oncogenes 
depending on the cellular environment in which they are expressed10. 
Mitchell et al. (2008) was the first to describe tumour-derived 
miRNAs in plasma11. Moreover miRNAs in plasma have shown to be 
stable as they avoid degradation by RNases11. A number of studies 
have shown miRNAs to be possible diagnostic biomarkers, which 
could substitute for the CEA and FOBT. 
     It is still uncertain whether miRNA can be used as biomarkers of 
CRC. Currently the literature present very different results of 
circulating miRNA expression in CRC patients compared to healthy 
control subjects.  
This qualitative systematic review gathers results from available 
studies in order to evaluate, whether circulating miRNAs potentially 
can be used as biomarkers in CRC.  
 
Methods  
Data sources and search strategy 
     In search of studies comparing circulating miRNA levels in 
plasma and serum from CRC patients and healthy individuals, a 
PubMed search was performed from 1966 up to March 2014. The 
search was performed with the following search criteria: 
("coloncancer" OR "colon cancer" OR "colorectal cancer" OR 
"colorectalcancer" OR "CRC" OR "CC") AND ("microRNA" OR 
"miR" OR "miRNA") AND ("plasma" OR "circulating" OR 
"serum"). 
 
Inclusion and exclusion criteria 
      Based on titles, abstracts or full texts, articles including the 
following criteria were included: (1) circulating miRNA in plasma 
samples from CRC patients; (2) comparison of circulating miRNA 
levels in CRC patients and healthy control subject; (3) statistical 
analysis of obtained data must include Receiver Operating 
Characteristic (ROC) curves and Area Under the Curve (AUC) 
values. 
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     Studies were excluded if they had any of the following subjects:  
(1) reviews; (2) written in any other language than English; (3) not 
miRNAs; (4) not cancer; (5) other cancer types than CRC or CC; (6) 
miRNA levels based only on tissue samples, thus not circulating 
miRNA; (7) miRNA as prognostic marker for risk of metastasis, 
relapse or poor outcome to chemotherapy; (10) based on stem cells 
or cell cultures 
Results 
Data selection 
     In selection of studies comparing circulating miRNA levels in 
plasma from CRC patients and healthy individuals, 89 articles were 
identified as potentially relevant. After careful selection according to 
in- and exclusion criteria as described above, eight articles were 
included in this review. Study selection flow-chart is seen in figure 1.
 
 
Figure 1: The figure shows the data selection. Eight articles were included in the systematic review. 
 
 
     The studies included a total of 777 cases of CRC and 687 control 
subjects. Sample population ranged from 71 to 329. Applicability of 
findings from the eight studies comparing circulating miRNA levels 
in plasma in CRC patients and healthy controls were compared. 
Comparison was based on ROC curve analysis. AUC values of each 
curve was classified after the following ranges: 0.90-1= excellent; 
0.80-0.90 = good; 0.70-0.80 = fair; 0.60-0.70 = poor; 0.50-0.60 = 
fail12, see table 1. 
 
Excellent 
     We found only one study which presented a panel of miRNA with 
an AUC value in the range of 0.90-1.00. The miRNA panel consisted 
of three miRNAs, miR-760, -291 and -92a and had an AUC value of 
0.9434, see table 3. The sensitivity and specificity was 83.3 % and 
93.1 % respectively. The result was based on 168 independent age 
and gender-matched individuals (100 CRC patients and 68 healthy 
controls) using quantitative Real-Time Polymerase Chain Reaction 
(qRT-PCR)4. We did not find any studies with single miRNA profiles 
of AUC values above 0.90, see table 2.  
 
Good 
     We found three different studies with four single miRNA profiles 
with AUC values in the range of 0.80-0.90, see table 1. Huang et al. 
(2009) found miR-29a with an AUC value of 0.844 and miR-92a 
with 0.838. The sensitivity was 69 % and 84 % respectively, and the 
specificity was 89.1 % and 71. 2 % for 29a and 92a respectively. The 
study was based on qRT-PCR with 120 CRC patients and 59 healthy 
controls7. Ng et al. (2009) used microarray and qRT-PCR and found 
miR-92 with the AUC value of 0.885 in a study based on 130 CRC 
patients and 75 healthy controls. The sensitivity was 89 % and the 
specificity was 70 %5. Wang et al. (2014) found miR-93 with the 
AUC value of 0.893 in a study based on 124 CRC patients and 117 
healthy controls. They performed microarray and qRT-PCR. The 
data concerning sensitivity and specificity was not available6. 
Furthermore we found four studies with a total of five miRNA panels 
with AUC values in the range of 0.80-0.90. Giráldez et al. (2013) 
found two miRNA panels. The first panel consisted of miR-19a and -
19b with an AUC value of 0.82 together with a sensitivity of 78.57 % 
and specificity of 77.36 %. The second panel consisted of miR-19a, -
19b and -15b with an AUC value of 0.84, see table 3. The sensitivity 
and specificity was 78.57 % and 79.25 % respectively. Giráldez and 
colleagues (2013) preformed microarray and qRT-PCR. The study 
was based on an independent cohort of 63 CRC patients and 73 
healthy controls13. 
     Huang et al. (2009) created a miRNA panel consisting of miR-29a 
and -92a with an AUC value of 0.883. The sensitivity and specificity 
of the panel was 83 % and 84.7 %7. Moreover Kanaan et al. (2013) 
had a miRNA panel consisting of two miRNAs, miR-431 and -139-
3p with an AUC value of 0.829. The sensitivity and specificity for 
the panel was 91 % and 57 %. The study was based on 45 CRC 
patients and 26 healthy controls14. Kanaan et al. (2013), used 
microarray and qRT-PCR14. In another study by Wang and 
colleagues (2014) a miRNA panel consisting of miR-7, -93 and -409-
3p with an AUC value of 0.866, was presented. The sensitivity was 
91 % and the specificity was 88 %6. 
 
Fair 
     In the range of 0.70-0.80 we found five studies with a total of 11 
different single miRNA AUC values, see table 1. 
Giráldez et al. (2013), found six different single miRNA with AUC 
values in the range of 0.70-0.80 (miR-18a, -19a, -19b, -15b, -29a, -
335). The data concerning sensitivity and specificity was not 
available13. Furthermore Ng et al. (2009) found one single miRNA 
(miR-17-3p) with an AUC value of 0.717 with a sensitivity of 64 % 
and a specificity of 70 %5. Wang et al. (2012) found two single 
miRNAs (miR-601, -760) with AUC values of 0.747 and 0.788 
respectively. For miR-601 the sensitivity was 69.2 % and the 
specificity was 72.4 %. For miR-760 the sensitivity was 80 % and the 
specificity was 72.4 %4. Furthermore Wang et al. (2014) found one 
single miRNA (miR-25) with an AUC value of 0.773. The data 
concerning sensitivity and specificity was not available6. Zanutto et 
al. (2014) found one single miRNA (miR-378) with an AUC value of 
•  21 articles excluded: 
 18 reviews, 3 not english 
89 articles identified through database searching 
•  36 articles excluded: 
 14 not cancer, 4 metastasis, 1 prognostic biomarker, 8 other cancer types 
 than CRC and CC, 3 not miRNAs, 1 therapeutic effect, 2 stem cells, 2 
 relapse, 1 sex hormone 
68 article titles read 
•  14 articles excluded:  
 5 miRNA levels based only on tissue samples, 3 therapeutic effect, 2 other 
 cancer types than CRC and CC, 1 relapse, 1 cell culture, 1 metastasis, 1 not 
 available 
32 article abstracts read 
•  10 articles excluded: 
 3 prognostic biomarkers, 1 other cancer types than CRC and CC, 1 cell 
 culture, 1 miRNA levels based only on tissue samples, 4 missing AUC 
 values. 
18 full articles read 
8 articles included in the systematic review 
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0.796. The study was based on a cohort consisting of 65 CRC 
patients and 70 healthy controls. The data concerning sensitivity and 
specificity was not available15. Luo et al. (2013) created a miRNA 
panel with 12 miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, 
-143, - 145, -181b, -342-3p and -532-3p) with an AUC value of 
0.745. The study was based on an independent cohort consisting of 
130 CRC patients and 199 healthy controls. The data concerning 
sensitivity and specificity was not available16. 
Poor 
     In the range of 0.60-0.70 we found two studies with a total of two 
different single miRNA AUC values. Wang et al. (2014) found one 
miRNA (miR-409-3p) with an AUC value of 0.604. The data 
concerning sensitivity and specificity was not available6. Zanutto et 
al. (2014) found one miRNA (miR-21) with an AUC value of 0.647. 
The data concerning sensitivity and specificity was not available15. 
Fail 
     In the range of 0.50-0.60 we found one study with a single 
miRNA AUC value. Wang et al. (2014) presented one miRNA (miR-
7) with an AUC value of 0.593. The data concerning sensitivity and 
specificity was not available6. 
 
 
 
Below fail 
     A single study by Zanutto et al. (2014) found two single miRNAs 
(miR-135b and -204) with an AUC value below 0.50. miR-135b had 
an AUC value of 0.477, and miR-204 had an AUC value of 0.49215. 
 
Discussion 
     This review provides an overview of studies concerning miRNA 
as biomarkers for CRC diagnosis published before March 2014. We 
have summarized the results of eight studies comparing miRNA 
levels in plasma from CRC cases and healthy control subjects. These 
studies presented a total of 25 dysregulated miRNAs in CRC 
patients; either upregulated or downregulated. Among these eight 
studies a total of 21 miRNAs were grouped in seven different 
miRNA panels to serve as potential biomarkers, while a total of 17 
single miRNAs were present as potential biomarkers. 
 
MicroRNA panel versus single microRNA 
     Currently it is uncertain whether single miRNAs or a combination 
of miRNAs in a panel is the most promising as a diagnostic 
biomarker of CRC4–7,13–16. Huang et al. (2010) examined miR-29a 
and -92a, and found AUC values of 0.844 and 0.838 respectively see 
table 2. 
 
Classification of AUC values 
Applicability AUC value Number of single miRNA AUC 
values 
Number of multiple miRNA 
panel AUC values 
Excellent 0.90-1.00 0 1 
Good 0.80-0.90 4 5 
Fair 0.70-0.80 11 1 
Poor 0.60-0.70 2 0 
Fail 0.50-0.60 1 0 
Below fail <0.50 2 0 
Table 1: The table shows the number of miRNAs found in the eight studies sorted in the 5 categories Excellent, Good, Fair, Poor, Fail and Below fail 
for single miRNA profiles and multiple miRNA profiles. The ranging is based on Area Under the Curve (AUC) values12.  
Single gene microRNA profile 
Author n = CRC / 
control 
Reference gene Upregulated microRNA Downregulated 
microRNA 
AUC 
Zanutto et al. 
(2014)15 
65 / 70 miR-16 miR-21, -135b, -378 miR-204 0.647 ; 0.477  0.796 ; 
0.492 
Wang et al. 
(2014)6 
124 / 117 miR-1228 miR-409-3p miR-25, -7, -93 0.604 ; 0.773 0.593 ; 
0.828 
Giráldez et al. 
(2013)13 
63 / 73 miR-16 miR-18a, -19a, -19b, -15b, -29a, -
335 
 0.70-0.80 
Luo et al. 
(2013)16 
130 / 199 miR-16 miR-18a, -20a, -21, -29a, -92a, -
106b, -133a, -143, -145 
  
Wang et al. 
(2012)4 
100 / 68 miR-16  miR-601, -760 0.747 ; 0.788 
Huang et al. 
(2010)7 
120 / 59 miR-16 miR-29a, -92a  0.844 ; 0.838 
Ng et al. (2009)5 130 / 75 RNU6B miR-17-3p, -92  0.717 ; 0.885 
Table 2: Shows number of patients, reference gene, regulation and Area Under the Curve (AUC) values of single gene microRNA profiles. n = 
number of patients in the study population. 
Multiple gene microRNA profiles 
Author n = CRC / 
control 
Reference 
gene 
microRNA panel AUC 
Wang et al. (2014)6 124 / 117 miR-1228 miR-93, -7, -409-3p 0.866 
Giráldez et al. 
(2013)13 
63 / 73 miR-16 miR-19a, -19b 0.82 
Giráldez et al. 
(2013)13 
63 / 73 miR-16 miR-19a, -19b , -15b 0.84 
Kanaan et al. 
(2013)14 
45 / 26 RNU6B miR-431, -139-3p 0.829 
Luo et al. (2013)16 130 / 199 miR-16 miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145, -181b, -
342-3p, -532-3p 
0.745 
Wang et al. (2012)4 100 / 68 miR-16 miR-29a, -92a, -760 0.943 
Huang et al. (2010)7 120 / 59 miR-16 miR-29a, -92a 0.883 
Table 3 shows Area Under the Curve (AUC) values of mutilple gene microRNA profiles. n = number of patients in the study population. 
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When they combined the two miRNAs in a panel, the AUC value 
increased to 0.883 due to an increase in the sensitivity and 
specificity7. If this panel was to be implemented as a diagnostic 
biomarker, it would mean that most of the patients were correctly 
identify as CRC patients, and more of the controls were correctly 
identified as healthy. Even though some of the AUC values for single 
miRNA are quite good, the multiple miRNA panels AUC values 
were generally better. Kanaan et al. obtained a sensitivity of 91 % 
and a specificity of 57 % for their miRNA panel (miR-431, -139-
3p)14. 
     This means that many will be tested positive correctly but the low 
specificity means that many will be tested positive while they 
actually are healthy. Wang et al. (2012) investigated two single 
miRNAs (miR-760 and miR-601), both found to be downregulated. 
They created and tested a panel consisting of three miRNAs (miR-
760, -29a, 92a) creating an AUC value of 0.943. They used miR-760 
in the panel because it had a better sensitivity as a single miRNA 
than miR-601. miR-29a and -92a were added to the panel based on 
results from previous studies4,7. When comparing single miRNAs 
with multiple miRNA panels, the AUC value increased significantly 
from the single miRNA to the miRNA panel4. Though Huang et al. 
(2010) and Wang et al.(2014) obtained good specificity and 
sensitivity values Wang et al. (2012) obtained the best AUC value, 
see table 3, and is therefore the most promising miRNA panel found 
in this review4,6,7. 
     Several CRC screening tests are available today. These include 
FOBT and CEA7. However because of low sensitivity and high cost, 
none of these are ideal as diagnostic screening tools6,7,17. FOBT has a 
sensitivity of 50-59.7 % and furthermore there is a great discrepancy 
between the investigated studies18,19.  CEA has shown a diagnostic 
sensitivity of 29.4 % and has shown a specificity ranging from 30-80 
%4,20. The low sensitivity indicates that more ill people are diagnosed 
as healthy, than what actually is the case. In this review CEA would 
be classified in the category fail, see table 1, and is therefore not in 
our opinion a useful novel diagnostic biomarker of CRC. The AUC 
values of single miRNAs are better than the AUC-value of CEA, but 
they are still not optimal and therefore a panel of circulating miRNA 
markers may improve the sensitivity and specificity of CRC 
screening.  
 
Microarray  
     Five out of eight studies used microarray prior to qRT-PCR to 
examine the expression of circulating miRNAs5,6,13,14,16. Microarray 
gives the possibility of searching for a very large number of 
miRNAs21. This is used to clarify which miRNAs to work with 
during qRT-PCR. The studies by Huang et al. 2010 and Zanutto et al. 
2014 did not use microarray, instead they chose miRNAs based on 
previous studies7,15. miRNA selection based on literature includes 
some of the commonly used miRNA, however there could be several 
other dysregulated miRNAs in the samples, that a microarray 
possibly could discover. Therefore it is an advantage to use 
microarray prior to qRT-PCR, to assure that other dysregulated 
miRNAs than those found in the literature will be evaluated. 
 
Reference genes for normalization of quantitative real-time 
polymerase chain reaction 
     Among the eight studies reviewed there are no consensus 
regarding endogenous reference gene for normalization of qRT-PCR, 
but miR-16 is the most frequently used6,7,14. Consensus is needed to 
evaluate the more correct applicability of miRNA as biomarkers of 
CRC. Normalization is an important step for accurate quantification 
of RNA levels with qRT-PCR7. From the eight studies reviewed in 
this article, miR-16, RNU6B, and miR-1228 were used as reference 
gene for qRT-PCR, see table 2. The discrepancy of miRNAs across 
different studies could possibly be caused by difference in the 
reference gene used for normalization. Huang et al (2010) found that 
miR-29a and miR-92a were significantly elevated in CRC plasma 
compared to healthy controls. They used miR-16 as a reference 
gene7. In contrast Wang et al (2014) found that miR-92a showed 
lower expression in CRC compared to healthy controls using miR-
1228 as a reference gene6.  
     It is essential for the study outcome that the reference gene is 
stable, for them to be used as controls. miR-16 has shown high 
stability in plasma for healthy individuals and CRC patientes13, but 
there is a high level in red blood cells22. Kirschner et al. (2011) 
showed that if the plasma samples had undergone hemolysis, it 
yielded a significant variation in miR-16 levels23. There have also 
been reports of problems with the stability of RNU6B24. RNU6B is a 
small nuclear RNA25. Huang et al (2010) compared miR-16 and 
RNU6B, and found that miR-16 was a better reference gene, because 
RNU6B showed to be unstable at room temperature7. 
     In a study by Hu et al. 2014, different reference gene, including 
miR-16, RNU6B and miR-1228, were tested, to see which had the 
best potential as a reference gene in various types of cancers 
including CRC26. They excluded RNU6B for further validation 
because it did not pass their quality control. In total they found that 
miR-1228 was the best reference gene, because it showed much less 
variation than miR-1626. 
 
Specificity of microRNAs in diagnosis of colorectal cancer 
     miRNAs are a major part of gene regulation in all cells, and 
certain circulating miRNAs have shown to be expressed by other 
cancer types than CRC27. Several studies have shown miR-21 to be 
upregulated in CRC, but it has also shown upregulation in breast 
cancer, gastric cancer, lung cancer, and esophageal cancer. Therefore 
it is important to examine whether the miRNAs used to diagnose 
CRC are dysregulated in other cancer types, or even in other kinds of 
diseases5,27,28. Some studies have already taken this into account. Ng 
et al. (2009) showed that elevation of miR-92 was not caused by 
either inflammatory bowel disease or gastric cancer5. 
     In summary miRNA panels are more promising as diagnostic 
biomarkers than single miRNAs, since they have better AUC values 
and higher sensitivity and specificity. More extensive validation 
studies are needed along with consensus about reference gene to 
ensure that the results are valid. Furthermore future studies should 
take into account that the same circulating miRNAs can be 
dysregulated not only in CRC but also in other cancer types and other 
disease. 
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